Prelude clinical performance is consistent with the NIPS literature, and is achieved without a FF failure threshold. Our results demonstrate that Prelude achieves high accuracy and a low test-failure rate in a large general obstetric population.
OBJECTIVE:
To estimate race/ethnic group correction factors for firsttrimester expanded Early-Onset Preeclampsia and Down syndrome screening markers. STUDY DESIGN: Maternal serum data from 12,876 patients in the United States including 2538 with mean arterial pressure (MAP) measurements and 1577 with uterine Artery Doppler pulsatility index (UtAD-PI) was analyzed. Weight-adjusted MoM values using the gestational age specific medians in the Caucasian group were calculated for maternal serum free beta hCG, pregnancy associated plasma protein A (PAPP-A), Alpha-Fetoprotein (AFP), Placental growth factor and Inhibin-A. Pairwise comparisons versus the Caucasian ethnic group were performed using the Wilcoxon test. African American patients were significantly higher for all serum analytes tested. In addition, UtAD-PI was significantly increased in this group. Asian patients demonstrated significantly higher Inhibin while Asian Indian patients were significantly higher for both Inhibin and PlGF. Hispanic patients were low for Free beta hCG and AFP but were slightly higher for Inhibin and UtAD-PI. CONCLUSION: All first trimester biochemical markers for Early Onset Preeclampsia and Down syndrome screening vary based on maternal race/ethnicity. UtAD-PI similarly varies based on race/ethnicity but no statistically significant change in MAP was observed in any ethnic group. Adjustments for each marker except MAP are indicated.
925 Non-reportable cell-free DNA: patient preferences, utility of repeat draw, and outcomes A NR result for a microdeletion but negative testing for above chromosomes were excluded. The primary outcome was aneuploidy or microarray abnormality on prenatal or postnatal genetic testing. Secondary outcomes evaluated were maternal characteristics, testing laboratory and methodology, and pregnancy and neonatal outcomes. Statistical analysis was performed utilizing Student's t-test and Fisher's exact test. RESULTS: Forty-six patients had NR cfDNA results, of which 31 (67.4%) had low fetal fraction (FF). Mean maternal age was 34.2 AE 4.9 years, and median gestational age at initial blood draw was 10.4 weeks (IQR 10.1 e 11.6). Median body mass index (BMI) was 28.1 kg/m 2 (IQR 23.6 e 32.6), and 43% were obese. Of these patients, 6 (13%) chose diagnostic testing, 38 (82.7%) opted for a repeat blood draw, and 2 (4.3%) declined additional testing. On repeat cfDNA sampling, 15 (39.5%) had a NR result and 23 (60.5%) had a reported result. Maternal age and BMI did not significantly differ in patients with a persistent NR result (p > 0.05); they were more likely to have maternal comorbidities (p ¼ 0.04) and a FF < 4% at time of initial blood draw (p ¼ 0.05). Obtaining a reportable or NR result on redraw did not differ by laboratory or testing method (p > 0.05). Patients with a repeat NR result were significantly more likely to undergo diagnostic testing (66.7% vs 4.3%, p < 0.01), which yielded an aneuploidy result in 20% of patients. Pregnancy outcomes did not significantly differ in patients with a repeat NR result (p > 0.05), detailed in the table. CONCLUSION: Almost half of repeat testing following a NR cfDNA result will again be NR. Repeat NR result is more likely in patients with medical comorbidities and FF < 4% at initial blood draw. It is associated with a 20% incidence of aneuploidy but not associated with an increased risk of adverse pregnancy outcomes. These test characteristics are important to consider when counseling patients on management following an initial NR cfDNA result. OBJECTIVE: Esoteric aneuploidy (non-trisomy 13/18/21) detection via expanded cfDNA prenatal screening presents several unique caveats; they are relatively common, often confined to the placenta, and have variable clinical impact. Herein we describe one of very few clinical reports of mosaic trisomy 2, in addition to the first and only cfDNA identified case of a true fetal mosaic trisomy 2 in the medical genetic literature. STUDY DESIGN: The maternal blood sample was subjected to DNA extraction, library preparation, and genome-wide massively parallel sequencing. Sequencing data were analyzed using a novel algorithm to detect trisomies and subchromosomal, genome-wide copy number variants 7Mb and larger. RESULTS: The patient presented to MFM at 10.7 weeks' gestation for genetic counseling and ultrasound. AMA and a prior trisomy 8 pregnancy prompted expanded cfDNA screening, yielding a trisomy 2 result (w 65% mosaicism, 6% fetal fraction) and residual risk for UPD. Amnio with SNP microarray testing was recommended.
Trisomy 2 is a relatively common finding per placental literature, usually confined to the mesenchyme, and carries an exceedingly low risk for true fetal mosaicism. A paucity of published trisomy 2 case studies was a substantial counseling limitation.
CVS was declined and fetal ultrasound showed normal growth and NT measurement at 10.7 weeks. However, a subsequent scan at 16 weeks showed a 2 vessel cord and a 1 week lag in humerus/femur length, increasing to a 2 week lag by 18 wks. Fetal echo showed hypoplastic LVOT and possible coarch of the aorta. Amnio at 20 weeks with SNP microarray revealed w20% mosaicism for Trisomy 2, no UPD. Pregnancy continued with growth lag measuring 5 weeks behind at 33 weeks. Palliative care was discussed, as prognosis was guarded.
PROM at 34.4 weeks prompted delivery of a 3lbs, 6oz (0%) neonate with APGARs of 2 and 8. An extended NICU stay ensued, with clinical outcome exceeding expectations. ASD repair occurred at 10 months. Now age three, the child is reportedly doing well overall, with physical exam noting small size, axial hypotonia, and motor delays. CONCLUSION: While many esoteric trisomies remain confined to the placenta and are of variable clinical consequence, the risk for true and occult fetal mosaicism cannot be dismissed. This case report illustrates the first known cfDNA identified, amnio confirmed true fetal mosaic for trisomy 2.
Prenatal diagnosis of genetic abnormalities:
Has it really moved to the first trimester? OBJECTIVE: Advances in genetic screening can identify patients at high risk for common genetic conditions early in pregnancy, and can facilitate early diagnosis and abortion. Less common abnormalities might only be diagnosed when invasive testing is performed after structural abnormalities are identified. Our objective was to compare gestational ages at diagnosis and abortion for genetic abnormalities identified based on screening and other genetic abnormalities. STUDY DESIGN: All prenatal diagnostic procedures in our department from 2012-2017 were reviewed, and singleton pregnancies terminated following diagnosis of genetic abnormalities were identified. Cases diagnosed as the result of screening tests were compared to remaining cases. Specific conditions were considered "screened for" if they can be suspected by NIPT, biochemistry, carrier screening, or if the patient was a known carrier of a single gene disorder. Since abnormal NT is associated with many genetic disorders, abnormal karyotype, microarray, or Noonan syndrome associated with abnormal NT were considered "screened for". Gestational age at abortion was the primary outcome. Fisher's exact test and MannWhitney U were used for statistical comparison. RESULTS: 267 cases were included. 230 (86%) of abortions were performed for genetic disorders considered screened for, with 209 (91%) of these for karyotype abnormalities, 9 (4%) for microarray abnormalities and 12 (5%) for single gene disorders. 37 (14%) of abortions were performed for conditions not included in screening or with any family history, with 12 (32%) of those for karyotype abnormalities, 18 (49%) for microarray abnormalities and 7 (19%) for single gene disorders. Invasive testing and abortion occurred at earlier median gestational age for those with conditions that were screened for: 12w2d vs. 15w5d; p ¼<.001, and 13w5d vs. 20w0d; p¼<.001. (Table 1) CONCLUSION: Most abortions were for common chromosomal abnormalities and single gene disorders that can be suspected early in pregnancy. About 1 in 7 were performed for less common conditions in patients not known to be at risk. Because many structural abnormalities associated with rare genetic conditions will not be identified until the second trimester, prenatal diagnosis and abortion occurred significantly later. Physicians and patients should be aware of the limitations of genetic screening, particularly when restrictions in abortion access can limit options in the second trimester. OBJECTIVE: To assess the frequency of familial versus de novo chromosome inversions during prenatal diagnosis and determine their clinical significance. STUDY DESIGN: A retrospective analysis of prenatally diagnosed inversions from a large reference lab database was performed. The data was reviewed for the type and frequency of various types of inversions, as well as their inheritance pattern. Variant inversion 9 was excluded. RESULTS: A total of 4088 (0.3 %) inversions were identified in a data set of 1.3 million invasive diagnostic procedures. Pericentric inversions accounted for 73% of the inversions (n¼2987), and the remaining 27% were paracentric. Common inversions involving chromosomes 1, 2, 10, and Y accounted for 46.7% of the total inversions (1911/4088). The most frequently identified inversion was inversion 2, inv2(p11q13), accounting for 23% of all inversions. The indications for invasive testing were as follows: advanced maternal age 1941 (47.5%), abnormal aneuploidy screen 935(22.9%), abnormal ultrasound findings 617(15%), previous chromosomal abnormality 449(11%), family history of a significant genetic disorder 69(1.7%), other indication 68(1.7%), and no indication in 10 cases. Excluding the common inversion group, mode of inheritance was available in 81% of cases (1767/2177), with 92% of inversions being inherited (1633/1767). There was a slight preponderance of maternal inheritance (53%). When an abnormal ultrasound was the
